Illumina (ILMN) announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization. “The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer’s environment and enable members to benefit from preventive genomics at a personalized level,” said Javier de Echevarria, CEO, Veritas Genetics and Chief Genomics Officer, Fuze Health.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina, Southern Co, Corning, Seagate, Microchip Insider Shifts
- Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating
- Roche genome pricing positive for Illumina, says TD Cowen
- Illumina announces launch of TruPath Genome
- Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating
